104

Table 58. Tuberculosis Cases and Percentages, by Completion of Tuberculosis Therapy 

(COT): Reporting Areas, 20141

Reporting area

United States

Total cases

9,398

Therapy <1 year indicated2,3,4

No. COT <1 year(%) COT(%)

7720 (90.1) (96.6)

Therapy >1 year indicated3,5

No.

526

COT(%)

(94.1)

Alabama

Alaska

Arizona

Arkansas

California

Colorado

Connecticut

Delaware

District of Columbia

Florida

Georgia

Hawaii

Idaho

Illinois

Indiana

Iowa

Kansas

Kentucky

Louisiana

Maine

Maryland

Massachusetts

Michigan

Minnesota

Mississippi

Missouri

Montana

Nebraska

Nevada

New Hampshire

New Jersey

New Mexico

New York State6

New York City

North Carolina

North Dakota

Ohio

Oklahoma

Oregon

Pennsylvania

Rhode Island

South Carolina

South Dakota

Tennessee

Texas

Utah

Vermont

Virginia

Washington

West Virginia

Wisconsin

Wyoming

133 112 (93.8) (99.1) 6 (100.0)

62 54 (94.4) (100.0) 3 (66.7)

193 130 (86.9) (96.2) 11 (100.0)

93 80 (76.3) (91.3) 4 (100.0)

2,130 1745 (88.3) (96.6) 126 (94.4)

64 52 (96.2) (100.0) 4 (100.0)

60 51 (98.0) (100.0) 6 (100.0)

21 20 (85.0) (95.0) 0 ...

32 27 (92.6) (100.0) 1 (100.0)

595 507 (92.9) (97.0) 21 (95.2)

334 282 (89.4) (96.1) 11 (100.0)

136 121 (98.3) (99.2) 6 (83.3)

11 8 (75.0) (87.5) 1 (100.0)

319 262 (89.7) (97.7) 22 (95.5)

108 91 (92.3) (97.8) 9 (100.0)

54 43 (90.7) (95.3) 4 (100.0)

40 35 (94.3) (100.0) 1 (100.0)

80 62 (95.2) (98.4) 5 (100.0)

121 103 (79.6) (93.2) 3 (100.0)

14 14 (78.6) (85.7) 0 ...

198 163 (89.6) (98.2) 11 (90.9)

199 163 (89.0) (96.9) 22 (100.0)

105 87 (95.4) (96.6) 5 (100.0)

147 122 (92.6) (98.4) 15 (93.3)

74 60 (81.7) (91.7) 1 (100.0)

79 65 (69.2) (80.0) 5 (100.0)

6 3 (100.0) (100.0) 0 ...

38 35 (68.6) (68.6) 0 ...

74 66 (93.9) (97.0) 2 (100.0)

11 10 (100.0) (100.0) 1 (100.0)

307 244 (92.6) (97.5) 23 (82.6)

8 5 (80.0) (100.0) 1 (100.0)

50 35 (94.3) (97.1) 1 (100.0)

202 167 (92.2) (97.0) 8 (100.0)

582 476 (95.4) (98.3) 39 (92.3)

195 159 (97.5) (100.0) 15 (100.0)

15 12 (58.3) (83.3) 3 (100.0)

156 121 (90.9) (96.7) 12 (83.3)

59 53 (94.3) (98.1) 2 (100.0)

77 58 (94.8) (98.3) 2 (100.0)

208 166 (80.1) (94.6) 13 (92.3)

21 17 (88.2) (88.2) 3 (100.0)

79 65 (95.4) (98.5) 6 (83.3)

151 128 (95.3) (100.0) 7 (85.7)

1,269 1025 (87.7) (95.0) 60 (93.3)

31 23 (100.0) (100.0) 4 (75.0)

2 2 (100.0) (100.0) 0 ...

198 170 (95.9) (100.0) 10 (100.0)

194 169 (91.1) (95.9) 7 (100.0)

13 12 (91.7) (100.0) 1 (100.0)

48 38 (89.5) (100.0) 3 (66.7)

2 2 (100.0) (100.0) 0 ...

American Samoa7

Fed. States of Micronesia7

Guam7

Marshall Islands7

N. Mariana Islands7

Puerto Rico7

Republic of Palau7

U.S. Virgin Islands7

1 0 ... ... 1 (100.0)

170 160 (92.5) (93.1) 2 (100.0)

56 51 (94.1) (96.1) 2 (50.0)

152 137 (92.0) (94.2) 2 (100.0)

25 10 (100.0) (100.0) 1 (100.0)

44 32 (90.6) (93.8) 1 (100.0)

14 7 (100.0) (100.0) 2 (50.0)

0 — — — — ... 1

Most recent year for which data are available.

2

Initial isolate susceptible to rifampin (n = 5,746) or susceptibility unknown (n = 90); culture negative (n = 1,622); culture status unknown (n = 272). 3

Number of cases in persons alive at diagnosis, with an initial regimen of one or more drugs prescribed. Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of 

Columbia).

4

Therapy <1 year indicated in persons alive at diagnosis with an initial regimen of one or more drugs prescribed, who did not die within one year of initiating therapy. Excludes persons with initial isolate 

rifampin resistant, or patient with bone and joint disease, meningeal disease or disease of the central nervous system, or pediatric patient (age <15) with miliary disease or positive blood culture or a positive 

nucleic acid amplification test on a blood specimen, and those who moved out of the country within one year of initiating treatment. 5

Initial isolate rifampin resistant, or patient with meningeal disease or bone and joint disease, or disease of the central nervous system, or pediatric patient (age <15) with miliary disease or positive blood 

culture or a positive nucleic acid amplification test on a blood specimen, and those who did not move out of the country or die during treatment. 6

Excludes New York City.

7

Not included in U.S. totals. 

Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.

See Technical Notes for description of completion of therapy calculation.